IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major IgA nephropathy (IgAN) markets reached a value of US$ 111.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 469.8 Million by 2034, exhibiting a growth rate (CAGR) of 13.98% during 2024-2034.
The IgA nephropathy (IgAN) market has been comprehensively analyzed in IMARC's new report titled "IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". IgA nephropathy (IgAN), commonly known as Berger's disease, is a rare autoimmune disorder affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the blood channels of the kidneys. An untreated IgA nephropathy results in kidney failure. During the early phases of this illness, there may be no apparent signs or symptoms, and it may take years or even decades for the afflicted person to recognize them. However, when the symptoms appear, the patient will notice blood in the urine, which is known as hematuria. Hematuria might also indicate damaged glomeruli. Another indication of this disease is the presence of foamy urine, which is caused by high amounts of protein present in it and is termed albuminuria. The diagnosis of IgA nephropathy begins with the healthcare professional reviewing the patient's medical and family history and then conducting tests. These tests include a urine examination to check for the presence of protein or blood in the urine, a blood test to detect the levels of cholesterol, protein, and wastes in the blood, and a glomerular filtration rate (GFR) test to determine how well his or her kidneys filter waste from the body. Aside from the tests described, a kidney biopsy is also conducted to see if any IgA antibody is present in the glomerulus to aid the body in fighting this sickness.
The rising prevalence of chronic glomerular diseases and the increasing unmet need for treatments are primarily driving the IgA nephropathy (IgAN) market. In addition to this, the widespread adoption of supportive measures, including lifestyle modification such as dietary sodium and protein restriction, smoking cessation, weight control, exercise as appropriate, etc., for effective management of the disease is also acting as another growth-inducing factor. Moreover, several key players are making significant investments in clinical trials for a better understanding of the disease pathophysiology and developing IgAN therapies for slowing the disease progression and managing symptoms such as high blood pressure, protein in the urine, swelling, etc. This, in turn, is further creating a positive outlook for the market. Apart from this, the governing agencies of various countries, along with non-governmental organizations (NGOs), are encouraging numerous health education campaigns to generate awareness regarding the risk associated with liver-related disorders, such as IgA nephropathy, thereby augmenting the global market. Several other factors, including a robust pipeline with novel therapeutic targets and the identification of novel biomarkers for better diagnosis as well as disease progression monitoring, are expected to drive the global IgA nephropathy market (IgAN) in the coming years.
IMARC Group's new report provides an exhaustive analysis of the IgA nephropathy (IgAN) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for igA nephropathy (IgAN) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the IgA nephropathy (IgAN) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: ?2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the igA nephropathy (IgAN) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the igA nephropathy (IgAN) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current igA nephropathy (IgAN) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the igA nephropathy (IgAN) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the igA nephropathy (IgAN) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the igA nephropathy (IgAN) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the igA nephropathy (IgAN) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of igA nephropathy (IgAN) ?
What will be the growth rate of patients across the seven major markets?
IgA Nephropathy (IgAN): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for igA nephropathy (IgAN) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the igA nephropathy (IgAN) market?
The IgA nephropathy (IgAN) market has been comprehensively analyzed in IMARC's new report titled "IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". IgA nephropathy (IgAN), commonly known as Berger's disease, is a rare autoimmune disorder affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the blood channels of the kidneys. An untreated IgA nephropathy results in kidney failure. During the early phases of this illness, there may be no apparent signs or symptoms, and it may take years or even decades for the afflicted person to recognize them. However, when the symptoms appear, the patient will notice blood in the urine, which is known as hematuria. Hematuria might also indicate damaged glomeruli. Another indication of this disease is the presence of foamy urine, which is caused by high amounts of protein present in it and is termed albuminuria. The diagnosis of IgA nephropathy begins with the healthcare professional reviewing the patient's medical and family history and then conducting tests. These tests include a urine examination to check for the presence of protein or blood in the urine, a blood test to detect the levels of cholesterol, protein, and wastes in the blood, and a glomerular filtration rate (GFR) test to determine how well his or her kidneys filter waste from the body. Aside from the tests described, a kidney biopsy is also conducted to see if any IgA antibody is present in the glomerulus to aid the body in fighting this sickness.
The rising prevalence of chronic glomerular diseases and the increasing unmet need for treatments are primarily driving the IgA nephropathy (IgAN) market. In addition to this, the widespread adoption of supportive measures, including lifestyle modification such as dietary sodium and protein restriction, smoking cessation, weight control, exercise as appropriate, etc., for effective management of the disease is also acting as another growth-inducing factor. Moreover, several key players are making significant investments in clinical trials for a better understanding of the disease pathophysiology and developing IgAN therapies for slowing the disease progression and managing symptoms such as high blood pressure, protein in the urine, swelling, etc. This, in turn, is further creating a positive outlook for the market. Apart from this, the governing agencies of various countries, along with non-governmental organizations (NGOs), are encouraging numerous health education campaigns to generate awareness regarding the risk associated with liver-related disorders, such as IgA nephropathy, thereby augmenting the global market. Several other factors, including a robust pipeline with novel therapeutic targets and the identification of novel biomarkers for better diagnosis as well as disease progression monitoring, are expected to drive the global IgA nephropathy market (IgAN) in the coming years.
IMARC Group's new report provides an exhaustive analysis of the IgA nephropathy (IgAN) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for igA nephropathy (IgAN) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the IgA nephropathy (IgAN) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: ?2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the igA nephropathy (IgAN) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the igA nephropathy (IgAN) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current igA nephropathy (IgAN) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the igA nephropathy (IgAN) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the igA nephropathy (IgAN) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the igA nephropathy (IgAN) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the igA nephropathy (IgAN) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of igA nephropathy (IgAN) ?
What will be the growth rate of patients across the seven major markets?
IgA Nephropathy (IgAN): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for igA nephropathy (IgAN) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the igA nephropathy (IgAN) market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IGA NEPHROPATHY (IGAN) - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 IGA NEPHROPATHY (IGAN) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IGA NEPHROPATHY (IGAN) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 IGA NEPHROPATHY (IGAN) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IGA NEPHROPATHY (IGAN) - UNMET NEEDS
10 IGA NEPHROPATHY (IGAN) - KEY ENDPOINTS OF TREATMENT
11 IGA NEPHROPATHY (IGAN) - MARKETED PRODUCTS
11.1 List of IgA Nephropathy (IgAN) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 IGA NEPHROPATHY (IGAN) - PIPELINE DRUGS
12.1 List of IgA Nephropathy (IgAN) Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ravulizumab - Alexion AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Batiraxcept - Aravive
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BION 1301 - Aduro BioTech
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Telitacicept - Yantai Rongchang Pharmaceutical
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. IGA NEPHROPATHY (IGAN) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 IGA NEPHROPATHY (IGAN) - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 IgA Nephropathy (IgAN) - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 IgA Nephropathy (IgAN) - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 IgA Nephropathy (IgAN) - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 IgA Nephropathy (IgAN) - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 IgA Nephropathy (IgAN) - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 IgA Nephropathy (IgAN) - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 IgA Nephropathy (IgAN) - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 IgA Nephropathy (IgAN) - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
15 IGA NEPHROPATHY (IGAN) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 IGA NEPHROPATHY (IGAN) MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IGA NEPHROPATHY (IGAN) - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 IGA NEPHROPATHY (IGAN) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IGA NEPHROPATHY (IGAN) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 IGA NEPHROPATHY (IGAN) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IGA NEPHROPATHY (IGAN) - UNMET NEEDS
10 IGA NEPHROPATHY (IGAN) - KEY ENDPOINTS OF TREATMENT
11 IGA NEPHROPATHY (IGAN) - MARKETED PRODUCTS
11.1 List of IgA Nephropathy (IgAN) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 IGA NEPHROPATHY (IGAN) - PIPELINE DRUGS
12.1 List of IgA Nephropathy (IgAN) Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ravulizumab - Alexion AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Batiraxcept - Aravive
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BION 1301 - Aduro BioTech
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Telitacicept - Yantai Rongchang Pharmaceutical
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. IGA NEPHROPATHY (IGAN) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 IGA NEPHROPATHY (IGAN) - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 IgA Nephropathy (IgAN) - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 IgA Nephropathy (IgAN) - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 IgA Nephropathy (IgAN) - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 IgA Nephropathy (IgAN) - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 IgA Nephropathy (IgAN) - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 IgA Nephropathy (IgAN) - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 IgA Nephropathy (IgAN) - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 IgA Nephropathy (IgAN) - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
15 IGA NEPHROPATHY (IGAN) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 IGA NEPHROPATHY (IGAN) MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
